Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology firm dedicated to the innovation, advancement, and commercialization of new technologies within the biotech sector. Its primary therapeutic focus revolves around a portfolio of product candidates, notably EP-104IAR, which is currently undergoing a Phase III clinical trial to address significant unmet medical needs, particularly offering pain relief for knee osteoarthritis. Another key candidate, EP-104GI, is progressing through Phase II trials for the treatment of eosinophilic esophagitis. Additionally, EP-104 is in preclinical development, exploring its potential for various inflammatory joint conditions, benign esophageal strictures, and applications via epidural delivery. Beyond these, the company is also developing drug candidates in the field of oncology. Originally established as Plaza Capital Partners Inc., the company rebranded to Eupraxia Pharmaceuticals Inc. in May 2012. Incorporated in 2011, Eupraxia Pharmaceuticals Inc. operates from its headquarters in Victoria, Canada.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of EPRX.TO is 17 and suggests 106% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr